DYN
HealthcareDyne Therapeutics, Inc. · Biotechnology · $3B
What is Dyne Therapeutics, Inc.?
Dyne Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious, genetically driven muscle diseases. Headquartered in Waltham, Massachusetts, the company is building a pipeline around its proprietary FORCE delivery platform.
Dyne Therapeutics develops disease-modifying therapeutics targeting rare muscle conditions, including myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company's FORCE platform is designed to deliver therapeutic molecules directly to muscle tissue more effectively than conventional approaches. Revenue is not yet generated from commercial products — the company is in the clinical development stage, funding operations through capital raises while advancing its pipeline toward potential regulatory milestones.
Dyne Therapeutics was incorporated in 2017 and is based in Waltham, Massachusetts.
- FORCE platform for targeted muscle tissue delivery
- Programs targeting myotonic dystrophy type 1 (DM1)
- Duchenne muscular dystrophy (DMD) therapeutic candidates
- Facioscapulohumeral muscular dystrophy (FSHD) program
- Rare skeletal, cardiac, and metabolic muscle disease research
Is DYN a Good Stock to Buy?
UQS Score rates DYN as Poor overall, reflecting significant challenges across multiple evaluation pillars.
Among the five pillars, Risk comes in at a Neutral rating — a relative bright spot suggesting the company's near-term financial exposure is not at the most extreme end for a clinical-stage biotech. This provides some runway context for investors evaluating the pipeline.
Quality, Moat, and Growth all register as Weak, reflecting the pre-revenue nature of the business and the absence of a durable competitive position that has yet to be commercially proven. Valuation is rated Elevated, meaning the market is pricing in significant future success.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does DYN pay dividends?
No — Dyne Therapeutics, Inc. does not currently pay a dividend.
Dyne Therapeutics does not pay a dividend, which is typical for clinical-stage biotechnology companies. All available capital is directed toward research, clinical trials, and platform development. Investors in DYN are generally seeking potential long-term value from pipeline success rather than current income.
When does DYN report earnings?
Dyne Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-commercial biotech, quarterly reports focus primarily on pipeline progress, cash runway, and operating expenses rather than revenue growth. Clinical trial updates and regulatory interactions tend to be the most market-moving disclosures.
For the most recent quarter's results and pipeline updates, visit Dyne Therapeutics' investor relations page directly.
DYN Price History
+0.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Dyne Therapeutics, Inc.?
Based on Dyne Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
DYN Long-term Outlook
The fundamental outlook for DYN is shaped by its early-stage pipeline and the binary nature of clinical trial outcomes. With Growth rated Weak and Valuation rated Elevated, the stock carries meaningful execution risk — positive trial readouts could shift the trajectory, while setbacks would weigh heavily. The Neutral Risk rating suggests the company maintains enough operational stability to continue advancing programs near-term, but the path to commercial viability remains long.
Growth drivers
- Clinical advancement of FORCE platform programs toward regulatory milestones
- Potential for pipeline expansion into additional rare muscle disease indications
- Growing unmet medical need in genetically driven neuromuscular diseases
Key risks
- Clinical trial failure or delays across key pipeline programs
- Elevated valuation leaves limited margin of safety if milestones slip
- Ongoing capital requirements typical of pre-revenue biotechs
DYN vs Peers
Dyne Therapeutics operates in a competitive rare-disease and neuromuscular biotech landscape alongside several other specialized companies.
Liquidia focuses on pulmonary arterial hypertension rather than muscle disease, representing a different rare-disease therapeutic niche.
Denali targets neurodegenerative diseases using its own transport platform, competing for similar investor interest in platform-driven rare-disease biotechs.
Catalyst has an approved commercial product in the neuromuscular space, giving it a revenue base that distinguishes it from earlier-stage peers like Dyne.
Frequently Asked Questions
What does Dyne Therapeutics do?
Dyne Therapeutics is a clinical-stage biotech developing treatments for genetically driven muscle diseases. Its FORCE platform is designed to deliver disease-modifying therapeutics directly to muscle tissue. Key programs target myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy.
Does DYN pay dividends?
No, Dyne Therapeutics does not pay a dividend. As a pre-commercial biotech, the company reinvests all capital into research and clinical development. Dividend payments are not typical for companies at this stage of development.
When does DYN report earnings?
Dyne Therapeutics follows a standard quarterly reporting cadence. For the most current earnings schedule and recent results, check the investor relations section of the company's official website.
Is DYN a good stock to buy?
The UQS Score rates DYN as Poor overall. Quality, Moat, and Growth are all rated Weak, while Valuation is Elevated. Risk is the one Neutral-rated pillar. This profile reflects a high-risk, pre-revenue biotech where outcomes depend heavily on clinical trial results. The full pillar breakdown is available to UQS Pro members.
Is DYN overvalued?
UQS rates DYN's Valuation as Elevated, meaning the current market price appears to embed significant expectations for future clinical and commercial success. For a pre-revenue company, this leaves limited margin of safety if pipeline milestones are delayed or missed.
How does DYN compare to its competitors?
Compared to peers like Catalyst Pharmaceuticals — which already has a commercial product — Dyne is at an earlier stage with no approved therapies yet. Denali Therapeutics shares a similar platform-driven approach in rare disease. Each company carries a distinct risk and pipeline profile worth evaluating separately.
What is DYN's market cap bracket?
Dyne Therapeutics is classified as a mid-cap company. This places it in a range where institutional interest is present, but the stock can still experience significant volatility tied to clinical trial news and broader biotech sentiment.
Who founded Dyne Therapeutics?
Dyne Therapeutics was incorporated in 2017. Founding and leadership details are publicly available through the company's official website and SEC filings for those seeking background on the management team.
Is DYN a long-term quality investment?
As a long-term quality indicator, the UQS Score rates DYN as Poor. Weak ratings across Quality, Moat, and Growth suggest the company has not yet established the durable fundamentals associated with long-term compounders. Pipeline success could change this picture, but the current profile reflects early-stage risk.
What is the main competitive advantage of Dyne Therapeutics?
Dyne's primary differentiator is its FORCE platform, which is designed to deliver therapeutic molecules specifically to muscle tissue. If validated clinically, this targeted delivery approach could provide a meaningful edge in treating rare muscle diseases where existing options are limited.
What sector does DYN belong to?
Dyne Therapeutics operates in the Healthcare sector, specifically within biotechnology. It focuses on rare and genetically driven muscle diseases — a niche within the broader rare-disease drug development space.
Is DYN a growth stock or value stock?
Based on UQS pillar labels, DYN does not fit neatly into either category in a favorable sense. Growth is rated Weak given the pre-revenue stage, and Valuation is Elevated — meaning investors are paying a premium without current financial performance to support it.
Unlock Full DYN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar score breakdown for DYN
- ✓Access full financial metrics and trend data
- ✓Compare DYN against sector peers side by side
- ✓Screen for higher-quality biotech alternatives
- ✓Get the complete analyst-style quality view for any ticker
Pro Analysis
DYN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | 12.2 | 0.0 | 11.0 | 2.4 | 59.7 | 0.0 | +0.5 |
| May 10, 2026 | 11.7 | 0.0 | 11.0 | 2.4 | 56.6 | 0.0 | +0.5 |
| May 9, 2026 | 11.2 | 0.0 | 11.0 | 0.0 | 56.6 | 0.0 | -0.5 |
| Apr 22, 2026 | 11.7 | 0.0 | 11.0 | 2.4 | 56.6 | 0.0 | -0.1 |
| Apr 2, 2026 | 11.8 | 0.0 | 11.0 | 2.9 | 56.6 | 0.0 | — |
DYN — Pillar Breakdown
Quality
— 0.0/100 (25%)Dyne Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 2.4/100 (20%)Dyne Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 59.7/100 (15%)Dyne Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Dyne Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Dyne Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for DYN.
Score Composition
Financial Data
More Stock Analysis
How is the DYN UQS Score Calculated?
The UQS (Unified Quality Score) for Dyne Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Dyne Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Dyne Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.